Interventions for the treatment of persistent post‐COVID‐19 olfactory dysfunction by O'Byrne, L, Webster, KE, MacKeith, S, Philpott, C, Hopkins, C, Burton, MJ

“…Participants received a 30‐day course of palmitoylethanolamide and luteolin or no intervention. Psychophysical testing was used to assess olfactory function at 30 days. …”

Endocannabinoid system mediates the association between gut-microbial diversity and anhedonia/amotivation in a general population cohort by Minichino, A, Jackson, MA, Francesconi, M, Steves, CJ, Menni, C, Burnet, PWJ, Lennox, BR

“…The model was set using alpha diversity (within-individual gut-microbial diversity) as predictor, serum and faecal levels of the endocannabinoid palmitoylethanolamide (PEA) as mediator, and anhedonia/amotivation as outcome. …”

Endocannabinoids control spasticity in a multiple sclerosis model. by Baker, D, Pryce, G, Croxford, J, Brown, P, Pertwee, R, Makriyannis, A, Khanolkar, A, Layward, L, Fezza, F, Bisogno, T, Di Marzo, V

“…In areas associated with nerve damage, increased levels of the endocannabinoids, anandamide (arachidonoylethanolamide, AEA) and 2-arachidonoyl glycerol (2-AG), and of the AEA congener, palmitoylethanolamide (PEA), were detected here, whereas comparable levels of these compounds were found in normal and non-spastic CREAE mice. …”